Letter from the Chairman
Where is the field of pharmaceutical and biotechnological development headed? There is increasing emphasis on closely examining the timelines and costs for developing new therapeutics with the importance of bringing through drugs and devices faster and more efficiently, reducing expenses, and maintaining quality.
The number of contract research organizations and site management organizations available to help companies meet their objectives in today's climate is ever increasing. Each claims to do it quicker, more cost effectively, and to a higher quality standard.
We, too, have earned a reputation for being exceedingly time and cost efficient, and for the high quality of product that we provide. We differ from our competitors; however, in the amount of experience and knowledge that we have in our area. It is not our objective to contract as many studies as possible. It is our goal to bring topical drug products to market as efficiently as possible. To do this, we dedicate significant internal resources on doing our own "research on research" to find the best methods to study and develop new products. We have a basic research laboratory, provide clinical and regulatory services using Good Clinical Practice (GCP), and provide market support. In contracting with our group, you can be assured that you will receive data gathered by people who truly understand the disease, the protocol, or the marketplace. In contracting with our group, you can be assured that you have hired a full support team that understands the process, can help you avoid potential pitfalls, and who have a long track record of success in this area.
Tapping into ORA means accessing recognized ophthalmic and dermatologic opinions; a clinical research staff with vast experience in these specialties who understand the pathophysiology of the indication, the appropriate selection of parameters, the logistical issues of conducting a clinical trial for that disease; a forward thinking regulatory staff familiar with topical drug products at the FDA; biostatistical consult who has contributed to the methods used in this area; an extensive network of trained investigators with proven support staff; a network of consultants in areas such as topical pharmacokinetics. We also are frequently contracted to provide business development services as may be required in licensing negotiations, due diligence assessments, venture capital discussions, and preparation of business plans.
I have been in the clinical research and development field for over thirty years. My philosophy has always centered around building long term relationships. As a result, we give our total commitment to a project to ensure success and satisfaction. Our continued presence in our field is testimony to our dedication and accomplishments. You have my personal assurance that should you choose to work with us, you will have the total support that has always characterized our performance and the success that comes from it.
Sincerely,
Mark B. Abelson, MD, CM, FRCS
Chairman and CSO
ORA, Inc.